DBV Technologies | DBVT - Operating Profit


DBV Technologies reported $-64.8M in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amarin USD -2.26M 564K Dec/2025
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
DBV Technologies USD -64.8M 16.9M Sep/2026
Galectin Therapeutics USD -11.29M 1.64M Jun/2024
Halozyme Therapeutics USD -63.72M 1.95M Jun/2026
Incyte USD -707.47M 1.41B Sep/2026
Insmed USD -81.83M 19.48M Sep/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
PTC Therapeutics USD 148.98M 103.09M Jun/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
United Therapeutics USD 330.8M 5M Jun/2026